研究单位：[1]Hoffmann-La Roche[2]Anyang Tumor Hosptial,Anyang,China[3]Cancer Hospital Chinese Academy of Medical Sciences.,Beijing,China,100021[4]Peking University First Hospital,Beijing,China,100034[5]The Affiliated Hospital of Military Medical Sciences(The 307th Hospital of Chinese PLA),Beijing,China,100071[6]Peking University Third Hospital,Beijing,China,100083[7]Beijing Cancer Hospital,Beijing,China,100142[8]Beijing Union Hospital,Beijing,China,100730[9]General Hospital of Chinese PLA[10]Department of Hematology,Beijing,China,100853[11]the First Hospital of Jilin University,Changchun,China,130021[12]Hu Nan Provincial Cancer Hospital,Changsha,China,410006[13]The Second Xiangya Hospital of Central South University,Changsha,China,410011[14]Changzhou First People''s Hospital,Changzhou,China,213003[15]Sichuan Provincial Cancer Hospital,Chengdu,China,610041[16]West China Hospital, Sichuan University,Chengdu,China,610041[17]Sichuan Provincial People''s Hospital,Chengdu,China,610072[18]Third Affiliated Hospital of Third Military Medical University,ChongQing,China,400042[19]The First People''s Hospital of Foshan,Foshan,China,510000[20]The First Affiliated Hospital of Fujian Medical University,Fu Zhou,China,350005[21]Fujian Medical University Union Hospital,Fujian,China,350001[22]Fujian Provincial Hospital,Fuzhou,China[23]Sun Yat-sen Memorial Hospital,Guangzhou,China,510000[24]The First Affiliated Hospital, Sun Yat-sen University,Guangzhou,China,510080[25]Nanfang Hospital, Southern Medical University,Guangzhou,China,510515[26]Guizhou Provincial People''s Hospital,Guiyang,China,550002[27]Guizhou Cancer Hospital,Guiyang,China,550004[28]Hainan provincial people''s hospital,Haikou,China,570311[29]Cancer Hospital of Hangzhou (Wushan District),Hangzhou,China,310002[30]Hangzhou First People''s Hospital,Hangzhou,China,310006[31]Harbin Medical University Cancer Hospital,Harbin,China,150081[32]The First Affiliated Hospital of Anhui Medical University,Hefei,China,230022[33]Inner Mongolia People''s Hospital,Hohhot,China,010017[34]Affiliated Hospital of Inner Mongolia Medical College,Hohhot,China,010050[35]The First Affilliated Hospital of Kunming Medical College,Kunming,China,650032[36]The First People''s Hospital of Yunnan Province,Kunming,China,650032[37]Yunnan Cancer Hospital,Kunming,China,650118[38]The First Affiliated Hospital of Lanzhou University,Lanzhou,China,730000[39]Gansu Cancer Hospital,Lanzhou,China,730050[40]Taizhou Hospital of Zhejiang Province,Linhai,China,317000[41]The First Affiliated Hospital of Henan UN of Science and Technology,Luoyang,China,471003[42]The 1st Affiliated Hospital of Nanchang Unversity,Nanchang,China,330006[43]The Second Affiliated Hospital to Nanchang University,Nanchang,China,330006[44]Jiangxi Cancer Hospital[45]First department of abdominal surgery,Nanchang,China,330029[46]Affiliated Hospital of North Sichuan Medical College,Nanchong,China[47]Nanjing 1st Hospital[48]Endocrinology Dept.,Nanjing,China,210006[49]Jiangsu Cancer Hospital,Nanjing,China,210009[50]Jiangsu Province Hospital,Nanjing,China,210036[51]The 81st Hospital of P.L.A.,Nanjing,China[52]Affiliated Hospital of Nantong University,Nantong,China,226001[53]Nan Tong Tumor Hospital,Nantong,China[54]The Affiliated Hospital of Medical College Qingdao University,Qingdao,China,266003[55]Ruijin Hospital, Shanghai Jiao Tong University School of Medicine,Shanghai,China,200025[56]Fudan University Shanghai Cancer Center,Shanghai,China,200032[57]Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai,China,200127[58]Changhai Hospital of Shanghai,Shanghai,China,200433[59]Changhai Hospital[60]Oncology,Shanghai,China,200433[61]Shaoxing People''s Hospital,Shaoxing,China,312000[62]Liaoning cancer Hospital & Institute,Shenyang,China,110042[63]Hebei Medical University Fourth Hospita
研究目的：
This prospective, multi-center, non-interventional study will evaluate the efficacy and safety of trastuzumab in routine clinical practice in Chinese participants with gastric or gastro-oesophageal cancer. The study will be conducted in 5 cohorts and eligible participants will be enrolled and assigned to the various cohorts according to human epidermal growth factor receptor 2 (HER2) status, disease stage and treatment with trastuzumab according to physician's decision. Treatment patterns and clinical outcomes in participants with gastric cancer in China will be evaluated. The total study duration is 60 months.
